We are advised by Eupry ApS that journalists and other readers should disregard the news release, FDA monitoring failures cited in nearly a third of pharmaceutical warning letters and rising, according to Eupry, issued 23-Jun-2026 over PR Newswire.

SOURCE Eupry ApS